Home » Stocks » FATE

Fate Therapeutics, Inc. (FATE)

Stock Price: $71.51 USD -0.78 (-1.08%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $71.00 -0.51 (-0.71%) May 13, 7:42 PM
Market Cap 6.64B
Revenue (ttm) 40.06M
Net Income (ttm) -184.96M
Shares Out 93.43M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $71.51
Previous Close $72.29
Change ($) -0.78
Change (%) -1.08%
Day's Open 73.70
Day's Range 68.27 - 76.59
Day's Volume 1,292,040
52-Week Range 26.15 - 121.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

With the trading day about halfway over, markets pushed higher into the weekend. The Nasdaq was the biggest winner on the day, with the index up over 1.3%.

Other stocks mentioned: ETSY, MNST, NOK, EPZM, IONS, NTLA
6 days ago - 24/7 Wall Street

FATE reports a wider Q1 loss on increased R&D expenses.

Other stocks mentioned: BMY, GILD, JNJ
1 week ago - Zacks Investment Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021

1 week ago - GlobeNewsWire

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...

2 weeks ago - GlobeNewsWire

Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline

2 weeks ago - GlobeNewsWire

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Other stocks mentioned: ALXN, ATVI, BKR, BMRN, ESPR, FLXN, RETA
2 weeks ago - 24/7 Wall Street

Here's why she likes them so much.

Other stocks mentioned: BEAM, TXG
3 weeks ago - The Motley Fool

Here's how shares a diversified e-commerce firm, an immunotherapy biotech, and an electronic agreement company can make you rich.

Other stocks mentioned: DOCU, SE
1 month ago - The Motley Fool

Eli Casdin on looking for opportunity in life sciences

YouTube video

Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.

Other stocks mentioned: NVTA, XLV
1 month ago - CNBC Television

The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading s...

1 month ago - Forbes

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for p...

1 month ago - GlobeNewsWire

These biotech companies are small, but they have tremendous growth prospects.

Other stocks mentioned: TWST
1 month ago - The Motley Fool

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Other stocks mentioned: BIIB, GILD, JNJ, ORTX, SANA, SGMO
1 month ago - GuruFocus

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...

Other stocks mentioned: DNLI, MRNA, MRTX, NVAX, SGEN, ZLAB
2 months ago - InvestorPlace

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pr...

2 months ago - GlobeNewsWire

FATE reports a wider Q4 loss on increased R&D expenses.

Other stocks mentioned: BMY, GILD, JNJ
2 months ago - Zacks Investment Research

Shares of Fate Therapeutics (NASDAQ:FATE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 64.86% over the past year to ($0.61), which m...

2 months ago - Benzinga

Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

2 months ago - GlobeNewsWire

The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while it's up 13% over the last ten trading days, and we believe the rally may continue in the near term. ...

3 months ago - Forbes

Time will always be on the investor's side.

Other stocks mentioned: CORT, CRSP, JNCE, LXRX
3 months ago - The Motley Fool

These two companies are at the forefront of innovation during our golden age of biotech.

Other stocks mentioned: BNTX
3 months ago - The Motley Fool

After a stellar 5x rise since the March 23 levels of last year, at the current price of around $114 per share we believe Fate Therapeutics stock, a biopharmaceuticals company focused on oncology and imm...

3 months ago - Forbes

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: CAG, ALDX, DMTK, GBIO, MRSN, ORI, REVG ...
3 months ago - Benzinga

If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.

Other stocks mentioned: BJ, GLNG, GTLS, HCAT, IIVI, LPSN, NVRO ...
3 months ago - Kiplinger

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

4 months ago - GlobeNewsWire

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

Other stocks mentioned: BBIO, EDIT
4 months ago - The Motley Fool

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...

4 months ago - GlobeNewsWire

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: MRNA, MRSN, NTLA, RARE
4 months ago - Zacks Investment Research

FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.

4 months ago - Zacks Investment Research

The biotech's natural killer cell therapies have real potential.

4 months ago - The Motley Fool

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FOLD, RARE, XLRN
4 months ago - Zacks Investment Research

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.

5 months ago - Zacks Investment Research

The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has increased by 37.8% (from $60.79 on December 6 to $83.77 on December 7). This is why.

5 months ago - Pulse2

The biotech reported great news on Friday and Saturday for two of its cancer immunotherapy candidates.

5 months ago - The Motley Fool

Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells

5 months ago - GlobeNewsWire

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...

6 months ago - GlobeNewsWire

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -24.14% and -25.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma

6 months ago - GlobeNewsWire

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for c...

7 months ago - GlobeNewsWire

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors... [Read more...]

Industry
Biotechnology
IPO Date
Oct 1, 2013
CEO
William Rastetter
Employees
314
Stock Exchange
NASDAQ
Ticker Symbol
FATE
Full Company Profile

Financial Performance

In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 112.00, which is an increase of 56.62% from the latest price.

Price Target
$112.00
(56.62% upside)
Analyst Consensus: Buy